AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval.
The transaction is subject to clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
For the purposes of the UK Listing Authority’s Listing Rule LR 10.4.1 R (Notification of class 2 transactions), the total book value of gross assets attributable to the PRV is equivalent to the full consideration of $95m. No operating profit or loss was attributable to the PRV in prior accounting periods at Sobi.
Media Relations
|
|
|
|
Gonzalo Viña
|
|
+44 203 749 5916
|
|
Rob Skelding
|
Oncology
|
+44 203 749 5821
|
|
Rebecca Einhorn
|
Oncology
|
+1 301 518 4122
|
|
Matt Kent
|
BioPharmaceuticals
|
+44 203 749 5906
|
|
Jennifer Hursit
|
Other
|
+44 203 749 5762
|
|
Christina Malmberg Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
| |
|
|
Investor Relations
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer Gruvris
|
BioPharmaceuticals (CV, metabolism)
|
+44 203 749 5711
|
|
Nick Stone
|
BioPharmaceuticals (respiratory, renal)
|
+44 203 749 5716
|
|
Josie Afolabi
|
Other medicines
|
+44 203 749 5631
|
|
Craig Marks
|
Finance, fixed income
|
+44 7881 615 764
|
|
Jennifer Kretzmann
|
Corporate access, retail investors
|
+44 203 749 5824
|
|
US toll-free
|
|
+1 866 381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
.svg)
